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Abstract
Background: The highly reactive aldehyde acrolein is a very potent endogenous toxin with a long half-life.
Acrolein is produced within cells after insult, and is a central player in slow and progressive “secondary injury”
cascades. Indeed, acrolein-biomolecule complexes formed by cross-linking with proteins and DNA are associated
with a number of pathologies, especially central nervous system (CNS) trauma and neurodegenerative diseases.
Hydralazine is capable of inhibiting or reducing acrolein-induced damage. However, since hydralazine’s principle
activity is to reduce blood pressure as a common anti-hypertension drug, the possible problems encountered
when applied to hypotensive trauma victims have led us to explore alternative approaches. This study aims to
evaluate such an alternative - a chitosan nanoparticle-based therapeutic system.
Results: Hydralazine-loaded chitosan nanoparticles were prepared using different types of polyanions and
characterized for particle size, morphology, zeta potential value, and the efficiency of hydralazine entrapment and
release. Hydralazine-loaded chitosan nanoparticles ranged in size from 300 nm to 350 nm in diameter, and with a
tunable, or adjustable, surface charge.
Conclusions: We evaluated the utility of chitosan nanoparticles with an in-vitro model of acrolein-mediated cell
injury using PC -12 cells. The particles effectively, and statistically, reduced damage to membrane integrity,
secondary oxidative stress, and lipid peroxidation. This study suggests that a chitosan nanoparticle-based therapy
to interfere with “secondary” injury may be possible.
Background
Substantial cellular injury caused by acute mechanical,
chemical, or biological insult is initially associated with
an instantaneous loss of plasma membrane integrity.
This facilitates the unregulated exchange of intracellu-
lar/extracellular ion species, and subsequently leads to
cell death [1,2]. The failure of this functional barrier
further induces incomplete oxygen metabolism within
the cell, and accelerates the production of highly reac-
tive oxygen species (so-called “free radicals”)s u c ha s
superoxide anions, hydrogen peroxide, and hydroxyl
radicals. The biochemical reactivity of such reactive oxy-
gen species (ROS) triggers the deterioration of lipids
within the inner domain of the cell membrane (lipid
peroxidation or LPO) producing endogenous toxins
composed of mainly aldehydes - especially acrolein
[3-7]. Unfortunately, the continuing production of toxic
aldehydes feed back to attack mitochondria, yet
untouched healthy membrane, and pass through intact
cell membranes to attack even nearby healthy cells. As a
consequence, the initial loss of membrane integrity in
response to the “primary injury” is the crucial step initi-
ating a “secondary injury” process in the nervous system.
Unchecked, these self - reinforcing processes influence
further collapse of mitochondria and oxidative metabo-
lism, continued deterioration of the cell membrane, the
further production of endogenous toxins, and ultimately,
cell death. In the past decade, significant neuroprotec-
tion was achieved by the topical, intravenous, or even
subcutaneous application of water-soluble polymers,
such as poloxamer 188, 1100, or polyethylene glycol
(PEG), as a rescue strategy to alleviate cell and tissue
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any medium, provided the original work is properly cited.damage following traumatic insults [8-16]. Such versatile
polymers have demonstrated their capability to induce
functional recovery at the cell level by initiating sponta-
neous molecular rearrangement of the lipid bilayers
through membrane fusion and integration [13].
This membrane-based recovery is initially seen as an
erasure of defects in the axolemma whose integrity is
the basis for action potential conduction. Measurement
of a rapid (minutes) recovery of compound action
potentials traversing crushed or cut guinea pig spinal
cord in organ culture [14,17] and an equally rapid
recovery of somatosensory evoked potentials traversing
the spinal cord lesion in “whole animal” guinea pig
injury models reveals the initial consequences of acute
neuroprotection/neurorepair by direct application - or
intravenous injection - of these polymers [6]. The longer
term, and stable, repair of critical anatomy has been
documented by intracellular tracing in severely injured
guinea pig spinal cord and adult rat brain [18,19]. This
in turn is responsible for significant behavioral recovery
of spinal cord and brain - mediated animal behavior
[12,20,21]. PEG and its derivatives have preferable mole-
cular weights and concentration ranges enabling them
to carry out this neuroprotection, which significantly
narrows the therapeutic window, and possibly their effi-
cacy without side effects in clinical trials [22]. For exam-
ple, higher concentration of PEG dissolved in sterile
saline produce viscosity problems for injectable solutions
whereas low molecular weight PEGs (< ~1000 kD) may
produce ethylene glycol poisoning [23,24]. Additionally,
it has been observed that bulky chains of poly (ethylene
oxide) tend to inhibit the efficient entry of such syn-
thetic polymers into cells where continued beneficial
activity is desired. According to a previous study, PEG
was accumulated only on the outside of cells for hours
instead of internalizing, where it can produce other ben-
eficial effects by acting on damaged mitochondria [25].
Nanoparticle-based drug delivery in which an acrolein-
trapping agent (hydralazine) is loaded within the con-
struction would be one of the ways to resolve these pro-
blems. We have observed anatomical and functional
recovery of axonal damage in guinea pig spinal cord after
intravenous injections of a simple solution of chitosan in
sterile saline. Indeed chitosan possess “sealing” qualities
similar to PEG and the Poloxamers (unpublished data to
appear elsewhere). Since it is now well-established that
the inactivation of acrolein can be achieved by the forma-
tion of hydrazone adjuncts on the basis of interaction
between acrolein and its trapping agent, hydralazine (Fig-
ure 1), we investigated the potential dual benefit by con-
structing a chitosan nanoparticle acting as 1., a
membrane fusogen, and 2., a hydralazine delivery vehicle
to ameliorate the damaging effects of acrolein exposure.
Results
Synthesis and characterization of hydralazine-loaded
chitosan nanoparticles
The molecular structures of chitosan, TPP, and DS are
shown in (Figure 2). The preparation of chitosan nano-
particles was conducted by adopting well-established
protocols [26-28]. The electrostatic interaction of posi-
tively charged amine moieties in hydralazine and chemi-
cally available functional groups of polyanions, such as
phosphoric acid in TPP and the sulfate group in DS, is
critical to facilitate the encapsulation of hydralazine
inside chitosan nanoparticles. The morphological or
physical phenomena of hydralazine encapsulation within
nanoparticles were characterized by TEM and zeta
potential/particle size analyzer as described above. In
contrast to solid particles, the chitosan particles are not
clearly identified once inside the cell due to some parti-
cle-formed aggregates which appeared as large agglom-
erates. We plan to work next with flow cytometry that
could perhaps offer a better opportunity to observe the
internalization of fluorescent-conjugated chitosan
nanoparticles.
In all experiments, chitosan nanoparticles were formed
at an equivalent mass ratio of chitosan to polyanion due
to the fact that high or low concentrations of chitosan
compared to polyanions tends to decrease the encapsu-
lation efficiency and/or promote aggregation of particles
[29]. Unloaded chitosan nanoparticles were measured to
have diameters in the range of ~250 nm ~300 nm (Fig-
ure 3C). The incorporation of hydralazine caused a
slight increase in the mean diameter of chitosan nano-
particles, resulting in an approximately 300 nm ~350
nm range in diameter. The surface charge of unloaded
chitosan nanoparticles ranged from 10.78 ± 1.54 mV to
-7.16 ± 3.69 mV for Chi-TPP and Chi-DS, respectively.
The number of negatively charged groups of the polya-
nions, TPP and DS, was responsible for this difference,
where DS (MW 9,000 ~ 20,000 Da) would possess the
predominant amount of sulfate groups per mole com-
pared to the amounts of phosphoric acid of TPP (MW
368 Da) at experimental conditions (pH 3~4). Positively
charged hydralazine loading did slightly increase these
values, corresponding to 14.51 ± 2.58 mV and -4.84 ±
1.38 mV for Chi-TPP/Hy and Chi-DS/Hy, respectively.
Analysis of particle morphology revealed that Chi-TPP
nanoparticles exhibited a well-defined spherical shape
with a solid and consistent structure (Figure 3A). On
the contrary, Chi-DS nanoparticles showed a clustered
spherical structure (Figure 3B). The opposite charge of
hydralazine and polyanions significantly contributes to
concomitant increase in the efficiency of encapsulation,
resulting in 15.8% and 23.5% for Chi-TPP/Hy and Chi-
DS/Hy, respectively. It is worthy to note that
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35% due to the association with DS compared to TPP.
This is possibly attributed to the presence of sufficient
negative charge densities in DS, which facilitated the
encapsulation of appreciable quantities of hydralazine
through the complexation process with chitosan.
In vitro release of hydralazine
The release profile of hydralazine from Chi-TPP and
Chi-DS nanoparticles was observed in Krebs’ solution
over 5 days duration. Apparently, both types of particles
showed burst release of 15 ~ 30% of the total deter-
mined concentration at 5 hr, which declined to a con-
stant, but slow, release rate over several days, as shown
in (Figure 4). It was likely that the rapid release was
caused by desorption of hydralazine loosely attached to
the surface of chitosan nanoparticles. The relative small
size of the hydralazine molecule would not be interfered
by the diffusion/dissociation process stemming from the
core or the pores of nanoparticles. In addition, the high
affinity and hydrophilic nature of chitosan with Kreb’s
medium provides space for penetration inside the parti-
cles to be able to dissolve the entrapped drug. It should
be noted that the molecular size of drug and ionic inter-
action with polyanions would be a major consideration
in deciding the rate of drug release.
The effect of hydralazine-loaded chitosan nanoparticles
on acrolein-mediated cell injury
Initially, functional tests (MTT and LDH exclusion
tests) were used to evaluate the response to different
chitosan formulations in PC 12 cells suffering from
acrolein exposure. We compared the effectiveness of
these formulations using entire cell populations in six
different groups: 1) a control group, 2) a 100 μMa c r o -
lein-exposed group, 3) a 100 μM acrolein-exposed and
Figure 1 The schematic illustration of nucleophile drug hydralazine and acrolein to form hydrazone which mediates acrolein toxicity
formed during lipid peroxidation. As a highly reactive a, b-unsaturated aldehyde, acrolein readily attacks nucleophilic centers of cell proteins
and DNA by Michael addition chemistry. Such intracellular toxicity induced by acrolein causes progressive destructive secondary reactions,
disrupting molecular and cellular systems. Scavenging of hydralazine inhibits acrolein-mediated toxicity and deactivates reactive carbonyl adducts
via the formation of hydrazone.
Figure 2 Chemical structures of (A) chitosan (Chi), (B) sodium tripolyphosphate (TPP), and (C) dextran sulfate (DS). (D) The schematic
illustration shows hydralazine incorporation into Chi-TPP and Chi-DS nanoparticles. The chitosan nanoparticles were formed spontaneously by
mixing an equivalent concentration of Chi and polyanions, TPP or DS. To achieve the incorporation of hydralazine into nanoparticles, hydralazine
was added in the prepared solution at a concentration of 1 mg/mL.
Cho et al. Journal of Biological Engineering 2010, 4:2
http://www.jbioleng.org/content/4/1/2
Page 3 of 11Chi-DS nanoparticle - treated group, 4) a 100 μMa c r o -
lein-exposed and Chi-DS/Hy nanoparticle - treated
group, 5) a 100 μM acrolein-exposed and Chi-TPP
nanoparticle - treated group, and 6) a 100 μMa c r o l e i n -
exposed and Chi-TPP/Hy nanoparticle - treated group.
First, we tested whether chitosan nanoparticles were
capable of sufficiently reducing acrolein cytotoxicity
using the MTT assay (Figure 5). In all experiments, the
various types of nanoparticles were added to the cell
medium after 15 min following the exposure to acrolein.
Acrolein-induced cytotoxicity was expressed as a
percentage of MTT activity, which is, as explained
above, an indicator of aberrant mitochondria function-
ing. Thus, MTT activity subsequent to 100 μMa c r o l e i n
exposure was decreased to 3.5 ± 2.9% of controls values.
In contrast, the treatment of poisoned cells with Chi-
TPP or Chi-DS increased survival to 44.5 ± 12.6%, and
37.8 ± 9.6% of controls after 5 hr, respectively (P <
0.05). Even more significant increase was observed after
application of hydralazine-entrapped chitosan nanoparti-
cles. Treatment with Chi-DS/Hy or Chi-TPP/Hy showed
very significant increase in cell viability, corresponding
Figure 3 The characterization of chitosan particles. TEM images of (A) chitosan nanoparticles incorporating TPP and hydralazine (Chi-TPP/Hy)
and (B) chitosan nanoparticles incorporating DS and hydralazine (Chi-DS/Hy). (C) provides data on the particle size, encapsulation efficacy, and
zeta potential for chitosan nanoparticle formulations. The encapsulation efficiencies showed a range from 15% to 23%, depending on the types
of polyanions. Mean diameter and surface charge of particles were slightly increased upon the incorporation of hydralazine due to the presence
of positively charged moieties.
Figure 4 The in vitro release profile of hydralazine from chi-TPP and chi-DS in Krebs’ solution. In both types of particles, initial burst
release occurred, yet subsequently fell to a constant and slow release observed over 5 days.
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respectively (P < 0.001). Hydralazine-loaded chitosan
nanoparticles improved cellular oxidative metabolism to
the greatest extent - and even better than control value.
As a complementary test, we observed the release of
LDH from PC 12 cells following acrolein attack. LDH
results were essentially consistent with the values
obtained from MTT assays. The cells exposed to 100
μM acrolein caused significant LDH increase, reaching
178 ± 25.4% of control values (Figure 6). Conversely,
LDH release was reduced to 117 ± 18% and 115 ± 10%
of control values by post-treatment with Chi-DS or Chi-
TPP, respectively (P < 0.01). Remarkably, hydralazine-
loaded chitosan nanoparticles, Chi-DS/Hy and Chi-TPP/
Hy, caused even more reduction in LDH release to a
level close to - or even below that of controls (untreated
cells; 100 ± 2% of control values), corresponding to 105
± 18% and 96 ± 19% of control values, respectively (P <
0.001). Additionally, we examined cell mortality using
the live-dead cell assay. Consistent with all results
described above, control cells in culture (with a charac-
teristic 90 ± 7% survival) dramatically fell to 29.8 ± 4%
at 5 hr when exposed to acrolein. Treatment of these
poisoned cultures with different types of chitosan nano-
particles improved survival to 60 ~ 70% (Figure 7).
The inhibition of plasma membrane peroxidation by the
application of hydralazine-loaded chitosan nanoparticle
The addition of hydralazine-loaded chitosan nanoparti-
cles to acrolein poisoned cultures was able to inhibit or
interfere with the generation of ROS and the associated
process of membrane LPO. The levels of ROS increased
approximately four-fold after exposure of cells to 100
μM acrolein, corresponding to 120 ± 14% of control
values (37 ± 19% (Figure 8A). Remarkably, the addition
of chitosan nanoparticles reduced the level of ROS up
to 39 ± 14% of control values - indeed close to that of
control groups (38 ± 21%, P < 0.01). Consistent with
this striking result, the level of LPO was also signifi-
cantly increased to 305 ± 22% of control values after
acrolein-induced injury (Figure 8B). Also consistent with
previous results, the LPO level corresponded to 91 ± 5%
(P < 0.001) of control values upon treatment with Chi-
DS/Hy, which was even lower than that of the control
group.
Discussion
Chitosan as a membrane “fusogen”
Chitosan, a biocompatible and biodegradable polymer,
has been widely tested in a variety of fields for the pur-
pose of developing treatments as diverse as wound heal-
ing, lung surfactant additives, and tissue engineering
[30-32]. Additionally, substantial efforts have been
devoted for the development and application of chitosan
nanoparticles as vehicles for drug delivery [26,33-35]. In
this regard, therapeutic efficacy based on chitosan nano-
particle systems confers several advantages: i) nano-
spheres composed of highly concentrated chitosan
molecules could serve as a “fusogen”.P r e v i o u ss t u d i e s
have demonstrated the effect of chitosan derivatives on
the fusion of small dipalmitoyl phosphatidylcholine
(DPPC) bilayers by inducing the formation of large
phospholipid aggregates [36-38], ii) in contrast to better
Figure 5 Cell viability test by MTT assay to demonstrate the recovery of mitochondria functionality. After 15 min of acrolein-mediated
attack, cells were exposed to Chi-TPP and Chi-DS incorporated with or without hydralazine. Direct localization of hydralazine released from
chitosan particles was observed, resulting in significantly enhanced viability. Results are expressed as percent control values ± SD (n = 5). *P <
0.05, ***P < 0.001.
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san nanoparticles of small size and hydrophilic character
a r ea l s oa b l et oc r o s st h ec e l lm e m b r a n et od e l i v e r
drugs or other molecules to the cytosol while avoiding
the rapid uptake by the reticuloendothelial system
(RES), as shown in (Figure 9) [39]. It is particularly
important that drugs carried inside nanoparticles would
be protected from denaturing, enzymatic degradation, or
the general biochemical environment, and iii) the encap-
sulation and release of drugs would be controllable by
manipulating several characteristics of the particles such
as size, surface functionalization, and loading
concentration. Moreover, the preference of the chitosan
moiety to target compromised membranes as discussed
above further shows the feasibility for the selective loca-
lization of a large amount of the drug at a specific and
desired site.
Recently, we have learned that chitosan, as a compo-
nent of an injectable solution, can serve as a novel ther-
apeutic agent after severe compression injury of guinea
pig spinal cord (unpublished observations). In such inju-
ries, progressive destruction of cells and tissues occurs
after mechanical trauma, however critical anatomy and
function was restored by the injection of chitosan.
Figure 6 Membrane permeability test by LDH assay to demonstrate the effects of acrolein and chitosan nanoparticles post-treatment.
LDH release was measured 3 hr after exposure to 100 μM acrolein followed by post-treatment with various chitosan nanoparticles. Chitosan
nanoparticles were demonstrated to be capable of restoring plasma membrane integrity, regardless of the presence of hydralazine. Results are
expressed as percent control values ± SD (n = 5). One-way paired ANOVA and Post Hoc Newman Keul’s test were used for statistical analysis. **P
< 0.01, ***P < 0.001.
Figure 7 Live/dead cell staining and the quantification of cell survival. (A) Representative fluorescent images of PC 12 cells, approximately
15 minutes after acrolein challenge (100 μM). Cells were exposed to Chi-TPP/Hy and Chi-DS/Hy, respectively. (B) PC 12 cells survival rate was
assessed as a ratio of live cells to total cells. Consistent with previous assays, survival was significantly increased as a result of the application of
both types of chitosan nanoparticles. Results are expressed as percent control values ± SD (n = 5).
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defect area in cells and tissues by hydrophobic interac-
tions. Conversely, at intact membranes, high surface
densities of lipid moieties inhibit the penetration of chit-
osan [36-38]. The mechanism underlying chitosan-
mediated membrane sealing and specific targeting of
injured membranes is still being investigated; however a
clear demonstration of the latter observation is
significantly persuasive that this approach holds unex-
pected merit in dealing with cell and tissue trauma.
T h ee v i d e n c ep r e s e n t e di nt h i sr e p o r ts u g g e s t st h e
potential usefulness of chitosan - as a nanoparticle base
likely due to its two-pronged attack on cell damage. We
emphasize that chitosan nanoparticles themselves are
capable of restoring cell viability by first mediating the
sealing of damaged membrane. We additionally showed
Figure 8 ROS and LPO upon the exposure to acrolein, and inhibition by various types of chitosan nanoparticles. (A) Quantification of
oxidized HE fluorescence intensity of control, acrolein-induced injury, and acrolein followed by chitosan nanoparticle treatment of PC 12 cell
groups (n = 5, **P < 0.01). (B) Measurements in control, acrolein-induced injured, and acrolein followed by chitosan nanoparticles treated PC 12
cell groups (n = 5, * P < 0.05, **P < 0.01, ***P < 0.001). The addition of chitosan nanoparticles following the exposure of acrolein showed
markedly decreased rate of oxidation of membrane lipids as well as lipid peroxidation.
Figure 9 Electron photomicrographs of (A) chi-DS and (B) chi-TPP cellular uptake by PC 12 neuronal cells.T h ea r r o w si n d i c a t et h e
presence of chitosan particles in PC 12 cells after incubation for 2 hours.
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interfering with the generation of ROS and LPO. This is
also due to its membrane reconstruction properties
rather than an ability to directly scavenge these toxins.
However upon conjugation with hydralazine, its poten-
tial therapeutic effects are dramatically enhanced. Chito-
san treatment alone did not provide neuroprotection
after exposure to acrolein - even in high concentrations
(unpublished observations). This fact suggested the
inclusion of hydralazine in the chitosan nanoparticle to
directly provide this function.
Acrolein-induced progressive neuronal degeneration and
rescue by hydralazine
It is widely accepted that traumatic injuries often dete-
riorate cell membrane integrity through multiple
mechanisms involving several biological processes and
biochemistries. Steady and progressive membrane rup-
ture and concomitant loss of intracellular contents
initially causes serious derangement of ionic species.
Especially, the unregulated influx of Ca
2+ into cyto-
plasm plays a key role in destabilizing and collapsing
the cytoarchitecture as well as membrane integrity by
activating numerous catabolic physiological and bio-
chemical processes such as ROS mediated LPO. There
is little evidence that free radicals (with half lives less
than seconds - even fractions of a second) are directly
toxic to cells. It is the downstream end product of
ROS stimulated LPO that produces actual toxins such
as a variety of aldehydes - acrolein being the most
potent. Compared to free radicals, acrolein has a half-
life many orders of magnitude longer [40]. Indeed,
highly reactive acrolein actively forms biomolecule
conjugates with proteins, DNA, and glutathione, which
further stimulates the generation of ROS and LPO.
The cytotoxicity of acrolein is known to be concentra-
tion-dependent. After exposure to 75 - 100 μM acro-
leoin, a majority of the PC 12 cell population was dead
within 4 hr [41]. In previous reports, we have shown
that the toxicity of acrolein can be significantly dimin-
ished after application of an acrolein-trapping agent
such as hydralazine. Hydralazine, a well-known nucleo-
phile drug, is able to immediately inhibit acrolein cyto-
toxicity by forming “hydrazones” through a scavenging
reaction (Figure 1) [42-44].
Notes on the fabrication, characterization, and use of
hydralazine-loaded chitosan nanoparticles in CNS trauma
and neurodegenerative diseases
There are many studies to take advantage of colloidal
particles as drug carriers. The use of colloidal drug car-
riers can facilitate not only site-specific drug delivery in
a designated region but also facilitate drug bioavailability
and therapeutic efficacy. On the basis of these consid-
erations, a variety of biocompatible and biodegradable
materials such as synthetic or natural polymers, lipids,
or solid (metal, semiconductor, magnetic, or insulator)
components have been intensively investigated [45,46].
First, liposome-based colloidal carriers have already
commercialized. Despite these advances, liposomes still
have some technical weakness with regard to the limita-
tions in reproducibility, stability, and low drug encapsu-
lation efficacy [47,48]. Solid particles such as silica
particles have been proposed as alternative drug carriers
that could potentially overcome such conventional pro-
blems. Silica particles with well-established synthesis
methods are easily incorporated with other substances
through surface modification, bioconjugation, and
entrapment [49].
On the other hand, the use of biodegradable poly-
meric drug carriers, either synthetic or natural, shows
great potential in controlled drug release by tuning their
biodegradability. Of these, chitosan is the one of the
most extensively studied - in particular, since it is com-
posed of reactive hydroxyl and amine groups, it tends to
adhere well to negatively charged surfaces, thus increas-
ing cellular transport [50].
B e c a u s ei ti sa na n t i h y p e r t e n s i v ed r u g ,t h es y s t e m i c
exposure of hydralazine will provoke problems related
to blood pressure management in hypotensive trauma
patients [51,52]. The use of our particulated system is
capable of significantly reducing systemic exposure of
drug since it is delivered to the intended site of action.
In spite of its potent therapeutic effects reported here in
vitro, our major challenge is to first, enhance the entrap-
ment efficacy of hydralazine in the chitosan nanoparti-
cle, and second, move the improved system to animal
models of spinal cord and brain injury [12,19].
The first issue arises due to the existence of charge
repulsion between cationic chitosan polymer (pKa = 6.5)
and positively charged hydralazine (pKa = 7.1). In an
attempt to enhance hydralazine encapsulation, two dif-
ferent kinds of polyanions were employed. Interestingly,
the encapsulation of hydralazine was particularly depen-
dent on the ionic interaction formed between chitosan
and polyanions, where the amount of negatively charged
groups of TPP and DS existed per mole was critical for
hydralazine association. As a consequence, Chi-TPP for-
mulation showed entrapment efficiency of 15.8% with
slightly increased positively charged surface property,
whereas Chi-DS exhibited an entrapment ratio of 23.5%
with negative surface, characteristics as shown in (Figure
3c). In both cases, after entrapment of hydralazine, the
nanoparticle formula showed some increase in diameter
and zeta potential value, indicating the presence of drug
through inter and intramolecular cross-linking. Both
particles, Chi-TPP and Chi-DS, displayed similar trends
in release behavior, where an initial burst release could
likely be a result of the desorption of hydralazine (which
is mostly attached on the surface of particles) and later
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release could be attributed to an increased viscosity
resulting from the concentration ratio of chitosan and
the polyanion, where a dense layer of chitosan might
cause a greater density of crosslinking and consequently
interfere with a swelling effect.
In summary, moving forward with this line of investiga-
tion requires exploring the stability of drug-loaded chito-
san nanoparticles on the basis of pH or chemical
crosslinking for a variety of compounds of interest to us.
Various molecular weight chitosan samples or water-
soluble chitosan molecules will be employed in this
ongoing research. The second challenge requires a diver-
sion towards toxicology studies to decipher any potential
side effects or unforeseen problems associated with the
chitosan particles or their cargo of hydralazine. Subse-
quently, we have much experience in the development of
behavioral, physiological, and anatomical models of SCI
and TBI, as well as access to veterinary clinical models of
neurotrauma to move these notions forward.
Materials and methods
Preparation of chitosan nanoparticles: Chi-DS and Chi-TPP
Chitosan with 85% deacetylation degree and of medium
weight (Chi, M.W. 200,000 Da), dextran sulfate (DS, M.
W. 9,000 ~ 20,000 Da), and sodium tripolyphosphate
(TPP, M.W. 367.8 Da) were purchased from Fluka/
Sigma-Aldrich. Two kinds of chitosan particles were
synthesized: Chi-DS and Chi-TPP. Briefly, Chi-DS was
prepared by complexation of Chi and DS as described
previously, where chitosan was dissolved at 0.10% (w/v)
with a 1% aqueous acetic acid solution while DS was
prepared in deionized water at the concentration of 0.5
mg/ml [26,28]. Equivalent volumes of chitosan and the
DS solution were mixed by magnetic stirring at room
temperature. Once the nanoparticle suspension started
to form, the mixture was stirred for another 20 min.
The formation of Chi-TPP nanoparticles was initiated
by ionic gelation mechanism based on the interaction of
cations and anions [27,33]. Chi-TPP nanoparticles were
formed spontaneously when equal volume of Chi (1.75
mg/ml) and TPP (2 mg/ml) solution were prepared and
stirred at room temperature. Hydralazine-loaded chito-
san nanoparticles were then immediately prepared by
incorporating equivalent volume of a Chi acidic solution
(1.75 mg/ml) and an aqueous TPP solution (2 mg/ml)
or aqueous DS solution (0.5 mg/ml) containing hydra-
lazing (1 mg/ml) while stirring with a magnetic bar.
Characterization of chitosan nanoparticles
Particle size and zeta potential measurements were car-
ried out with a zeta-potential/particle size analyzer
(Zetasizer). To begin, samples were diluted in deionized
water and measured in an automatic mode. All mea-
surements were performed in three ~ five repetitions.
The morphology of chitosan nanoparticles was observed
by transmission electron microscopy (JEOL 2000FX).
Encapsulation and release of hydralazine from particles
The amount of hydralazine encapsulated in the chitosan
nanoparticles was measured by UV spectrometry follow-
ing centrifugation of the samples at 15000 rpm for 30
min. The difference between the total amount of hydra-
lazine used for the formation of chitosan nanoparticle
loaded with hydralazine and untrapped hydralazine in
the supernatant solution was calculated to assess the
efficiency of encapsulation.
Hydralazine encapsulation efficiency
total hydralazine fre

 e e hydralazine
total hydralazine
To observe the release behavior of hydralazine from
chitosan nanoparticles, a modified Krebs’ solution (pH
7.2) that contained 124 mM NaCl, 2 mM KCl, 1.2 mM
KH2PO4,1 . 3m MM g S O 4, 2 mM CaCl2,2 6m M
NaHCO3 was used. The release of hydralazine sus-
pended in this Krebs’ s o l u t i o nw a so b s e r v e da saf u n c -
tion of the concentration of incorporated hydralazine.
The released hydralazine was extracted at a different
time-interval and centrifuged to permit measurement by
UV spectroscopy. The concentration was then calculated
by linear equation to determine the hydralazine release
curve.
Cell cultures
PC 12 cells with a density of 1 × 10
6 cells/mL were
grown in Dulbecco’s modified eagle’s medium (DMEM;
Invitrogen) supplemented with 12.5% horse serum, 2.5%
fetal bovine serum, 50 U/ml penicillin, and 5 mg/ml
streptomycin - at an incubator setting of 5% CO2 and
37°C. After trypsinization and centrifugation, cell pellets
were resuspended in Hank’s balanced salt solution
(HBSS) for the exposure to acrolein and subsequent
treatment with chitosan nanoparticles. Acrolein (100
μM) was prepared fresh daily in PBS solution. The Chi-
TPP/Hy or Chi-DS/Hy suspensions were applied at a
concentration of 20 μl/ml in medium with a delay of 15
min after the application of acrolein.
Determining the integrity of cell membranes: The lactate
dehydrogenase (LDH) exclusion assay
The reduction of nicotinamide adenine dinucleotide
(NAD) by the presence of LDH results in the formation
of a tetrazolium dye. The interpolation of the produc-
tion of the dye can permit determination of the amount
of LDH by standard spectrophotometric techniques. We
use the LDH assay (Sigma) to assess cell membrane
integrity after exposure of cells to the toxin acrolein.
The amount of release of LDH from the cytoplasmic
compartment to the supernatantis indicative of mem-
brane permeability. Ordinarily, there would be little to
no loss of LDH from intact cells. However in this assay,
the necessary handling of cells results in some
Cho et al. Journal of Biological Engineering 2010, 4:2
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Page 9 of 11“background” loss of LDH which must be taken into
account relative to the damage produced by acrolein-
mediated attack on membranes. The background absor-
bance measured at 660 nm was subtracted from the
reading at 492 nm. Cells were grown in 12-well plates at
ad e n s i t yo f1×1 0
6 cells/well in HBSS were used for
LDH release into the medium and determination of
total LDH, respectively.
LDH 
Amedium  nm  nm
Atotal  nm  nm
(%)
()
()




492 660
492 660
100
MTT assay for cellular viability
Upon exposure to acrolein, the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide tetrazolium (MTT,
Sigma) assay was used to determine the overall viability
of the sample cells as it is an indicator of oxidative
metabolism. The assay assesses the activity of a mito-
chondrial dehydrogenase enzyme which is detectable
only from viable cells by the color change of tetrazolium
rings from pale yellow MTT to dark blue formazan
crystals. Quantification of these shifts was evaluated by
spectrophotometric measurement. PC 12 cells were
seeded in 12-well plates at 1 × 10
6 cells/well in HBSS.
MTT reconstituted in PBS was added to each well.
After incubation, formazan crystals were pelleted by
centrifugation, and dissolved in a MTT solubilization
solution. The absorbance was read at 550 nm minus the
background at 660 nm.
Cell mortality using the Live - Dead cell assay
To assess the impact of acrolein exposure on living cells,
the determination of the number of live and dead cells
in the total cell population was performed by the appli-
cation of a two-color fluorescence assay (Biovision Inc.).
This assay can selectively stain the live and dead cells
using calcein AM (Cal AM) and ethidium homodimer
(EthD-1). Cal AM typically crosses the cell membrane
into living cells and consequently the cleaved calcein
fluorophore is released which possess a strong green
fluorescence with an emission wavelength of ~525 nm
and an excitation wavelength of ~485 nm. In contrast,
EthD-1 can only diffuse into dead or dying cells and
produces a red fluorescence at ~625 nm when excited
at ~525 nm. The test PC 12 cells were cultured in 12-
well plate at 1 × 10
6 cells/well in HBSS, and subse-
quently incubated in Cal AM and EthD-1 for 5 minute.
Using fluorescent microscopy, cell viability was calcu-
lated and expressed as a percentage.
Measurement of reactive oxygen species (ROS) and lipid
peroxidation (LPO)
The production of reactive oxygen species accelerates as
a result of cell membrane damage which in turn drives
LPO and toxic aldehyde production. Therefore a
comparison of the levels of ROS and LPO following
acrolein-exposure and post-treatment with chitosan
nanoparticles provides clues for examining the state of
cell deterioration in response to oxidative stress. The
cultured cells were immersed in 1 mL of PBS with
hydroethidium (HE, Invitrogen) at a final concentration
of 1 μM for 10 min in the dark. Concentrations of ROS
weredetermined by the chemi-luminescence assay based
on the conversion of hydroethidine (HE) to ethidium (E
+) in the presence of intracellular superoxide anion (O2
-
). Subsequently, samples were analyzed with epifluores-
cence on an Olympus BX61 microscope using a stan-
dard rhodamine cube (545/590 nm excitation/emission
respectively), and quantified using Image J software
(NIH) to measure the amount of ethidium bromide
uptake. LPO was measured using a lipid hydroperoxide
assay (Cayman Chem. Co.). Once cells were exposed to
acrolein, the level of hydroperoxides was directly mea-
sured utilizing their redox reactions with ferrous ions.
Subsequently, the absorbance of each sample was read
at 500 nm using a spectrophotometer (SLT spectra plate
reader). Lipid peroxidation was calculated and expressed
as a percentage of control values.
Statistical analysis
One-way ANOVA was used to determine the statistical
significance between control and experimental groups
using InStat software. Results are expressed as mean ±
SD. P ≤ 0.05 was considered statistically significant.
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